Gossamer Bio Inc Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $53.3M-53.5% YoYTTM through 30 Jun 2026
Net Income -$125.2MTTM through 30 Jun 2026
Free Cash Flow -$162.6MTTM through 30 Jun 2026
Margins
| Current | |
|---|---|
| Gross Margin | -149.8% |
| EBITDA Margin | -311.7% |
| Operating Margin | -311.7% |
| Net Margin | -235.0% |
Returns
133.2%ROE
-162.9%ROA
Balance Sheet Health
Debt / Equity-1.24x
Current Ratio2.64x
Net Debt$100.8M
Cash & Equivalents$41.1M
Quality Metrics
Altman Z-Score-33.95
Piotroski F-Score1 / 9
FCF Margin-305.2%
Earnings-Beat Rate25.0%
Multi-Year Trend
RevenueFY2025: $48.5M
Diluted EPS-$0.66TTMFY2025: $-0.75
Dividend
No dividend
Capital Allocation
Capex Intensity0.0%
Segment Performance
| Segment | Revenue | YoY | Outlook |
|---|---|---|---|
| Collaboration Services | $17M | +71.5% | View detailsPlanned NDA submission for seralutinib in PAH is targeted for September 2026, subject to FDA Type B pre-NDA meeting outcomes. |
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.